Amgen, J&J Myasthenia Gravis Data Show Potential Market Opportunities

 
• By Alaric DeArment

The companies presented data for Uplizna and nipocalimab in gMG at a medical meeting. J&J’s nipocalimab is pending for approval in the disease, while Amgen is working on submitting Uplizna.

Concept of Myasthenia Gravis written on sticky notes isolated on Wooden Table.
Amgen and J&J presented data in generalized myasthenia gravis at the AANEM meeting • Source: Shutterstock

More from Clinical Trials

More from Therapy Areas